A new drug, termed ixazomib, is to be used in combination with standard treatments and has been made available on the Cancer Drug Fund.
Browsing: multiple myeloma
Researchers from the Dana-Farber Cancer Institute (MA, USA) have conducted the largest genomic analysis of patients with smoldering multiple myeloma –a precursor to multiple myeloma. The results may offer a new insight into the mechanism of multiple myeloma progression.
We spoke with a key study investigator of the multiple myeloma ENDEAVOR trial to explore the trial in more detail and to discover the potential clinical application of its overall survival findings.
This review article from Future Oncology summarizes the efficacy of the latest therapeutic agents available for the treatment of patients with relapsed multiple myeloma.
Researchers discover that inhibiting EZH2 leads to the reduced expression of specific oncogenes involved in the development of multiple myeloma
Could 3D tissue-engineered bone marrow have any advantages over classic tissue culture screenings in assessing drug efficacy in multiple myeloma?
An experimental antibody therapy has been determined to reduce the number of tumor-driving cancer stem cells by up to 50% in multiple myeloma patients in a preliminary clinical trial.
Could B-cell maturation antigen – present on the surface of malignant plasma cells – be an ideal antigen for targeted immunotherapy for multiple myeloma? Find out more in this peer-reviewed article from Immunotherapy.
This review article from Epigenomics explores the role of DNA methylation in the repression of tumor suppressor protein-coding genes or non-coding miRNAs in multiple myeloma.
First-in-human study combines natural killer cells with high-dose chemotherapy and stem cell transplantation for multiple myeloma therapy and reports few of the side effects associated with standard treatments.